In the OTC drug industry, your product is only as good as the partners who help you make it. The raw material supplier who sources your active pharmaceutical ingredient (API), the contract manufacturer (CMO) who blends and packages your product, and the contract testing lab whose results determine the release of each batch all pose a real quality risk to your product.
So how do you choose the right ones? And once you’ve chosen, how do you stay confident that they’re performing?
The answer lies in a disciplined, structured approach to supplier qualification and ongoing oversight, one of the most critical components of any Supply Chain Quality Management (SCQM) program.
Qualifying Raw Material Suppliers
The first rule of supplier qualification: cost should never be the primary driver.
Yes, cost matters. But selecting a raw material supplier, particularly one who will supply an API, based primarily on price is a shortcut to long-term problems. Instead, assess potential suppliers on three dimensions before you ever place an order:
- Capabilities: Can they actually produce the grade and specification you require?
- Capacity: Can they reliably meet your volume needs without compromising quality?
- Compliance History: What does their regulatory track record look like? Have they been cited in FDA Warning Letters or import alerts?
Once a supplier clears that initial screen, qualify them formally. For API suppliers, that means conducting an on-site audit, a virtual audit, or at a minimum a thorough paper audit using a GMP/Quality Questionnaire. Then put a Quality Agreement in place, one that explicitly includes Change Control provisions so you’re notified before they make any modifications to materials, processes, or testing methods that could affect your product.
Validating the Certificate of Analysis
Here’s a step that too many companies skip: validate the supplier’s Certificate of Analysis (C of A) before trusting it.
Send three different lots of the raw material to an independent laboratory and test every parameter listed on the C of A. Compare results:
- Poor correlation signals low credibility in the supplier’s reported data. That’s a red flag that warrants further investigation or disqualification.
- Good correlation builds confidence in the supplier’s testing integrity and gives you documented justification for “skip-lot” or reduced incoming testing in the future, which can meaningfully reduce your operational costs.
This validation step applies to both APIs and excipients. It’s not optional if you want a defensible quality program.
Qualifying Contract Manufacturers
The guidance is similar for CMOs, with one important addition: you really should see the facility.
Contract drug manufacturing is a high-stakes activity. Before entrusting a CMO with your product, physically visit (or conduct a virtual audit of) the facility. Inspect the equipment. Review critical SOPs and batch records. Understand how they handle deviations, OOS results, and change control.
Once engaged, ongoing oversight is essential:
- Request the full Batch Record, not just the C of A, for every batch manufactured on your behalf. Your QA team should review and approve each one.
- Use third-party spot testing. Periodically send finished batches to an independent lab for confirmatory testing. This isn’t about distrust; it’s about maintaining an objective quality check.
- Track and trend critical data. Patterns in processing data often reveal issues before they become failures.
- Make your vigilance known. A CMO that knows you’re paying attention is a CMO that stays sharp.
Qualifying Contract Testing Laboratories
The same due diligence framework applies to contract testing labs, with particular emphasis on seeing the lab before you rely on it.
Testing laboratories are where quality decisions are made. Errors in the lab can result in good product being rejected or, more dangerously, bad product being released. Before engaging a lab:
- Audit the facility: equipment, SOPs, records, and data integrity practices.
- Ensure the Quality Agreement includes Out-of-Specification (OOS) investigation provisions.
- Routinely request raw data, including chromatograms, spectra, and supporting documents, not just the final test report.
Ongoing vigilance here is non-negotiable. Periodic re-audits and consistent data review keep labs accountable and catch issues before they become systemic.
The Takeaway
Supplier and partner qualification isn’t a one-time event. It’s a lifecycle of due diligence: rigorous upfront selection, structured onboarding with Quality Agreements, and sustained oversight through monitoring, auditing, and data review.
Companies that invest in this infrastructure are better positioned to prevent quality failures, manage costs over time, and protect the brand equity they’ve built.
If you’re ready for a partner who can consult and advise on your Supply Chain Quality Management and audits, contact us today.